

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 9/107, 9/127, 47/22		A1	(11) International Publication Number: WO 97/03651
			(43) International Publication Date: 6 February 1997 (06.02.97)
(21) International Application Number: PCT/GB96/01758		(81) Designated States: AU, CA, GB, JP, NO, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 22 July 1996 (22.07.96)			
(30) Priority Data: 9514878.9 20 July 1995 (20.07.95) GB		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): DANBIOSYST UK LIMITED [GB/GB]; Albert Einstein Centre, Highfields Science Park, Nottingham NG7 2TN (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): ILLUM, Lisbeth [DK/GB]; 19 Cavendish Crescent North, The Park, Not- tingham NG7 1BA (GB). WASHINGTON, Clive [GB/GB]; 143 Seaburn Road, Toton, Nottingham NG9 6HJ (GB). LAWRENCE, Simon [GB/GB]; "Lugano", Sunnybox Lane, Slindon Common, Nr. Arundel, West Sussex BN18 0LX (GB). WATTS, Peter [GB/GB]; Flat 2, 47 Highfield Road, West Bridgford, Nottingham NG2 6DR (GB).			
(74) Agent: BASSETT, Richard; Eric Potter Clarkson, St. Mary's Court, St. Mary's Gate, Nottingham NG1 1LE (GB).			

(54) Title: LIPID VEHICLE DRUG DELIVERY COMPOSITION CONTAINING VITAMIN E

(57) Abstract

The present invention provides a drug delivery composition comprising a lipid vehicle containing a drug and Vitamin E to enhance the solubility of the active drug in the lipid vehicle. The composition is particularly useful for drugs which are poorly soluble. The composition may be in the form of a liposome or an oil-in-water emulsion. The Vitamin E may be mixed with a pharmaceutically acceptable oil such as a marine oil or a vegetable oil.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## LIPID VEHICLE DRUG DELIVERY COMPOSITION CONTAINING VITAMIN E

The present invention relates to a drug delivery composition comprising a lipid vehicle, and more particularly to a drug delivery composition  
5 comprising vitamin E to enhance the solubility of the drug in the lipid vehicle.

Drugs can be administered by a variety of routes to include oral and parenteral. It is often useful to have available an injectable form of a drug  
10 in order to provide rapid onset of action, or direct delivery to its site of action via the blood stream. A number of drugs are difficult to administer by injectable routes because they are poorly soluble in water such that an excessive volume of solution would be required in order to deliver a dose of the compound. Various approaches known to those skilled in the art  
15 can be used in order to increase the loading of the drug in the parenteral product. These include the use of cosolvents, surfactants, liposomes and emulsions.

Emulsion systems have long been used for pharmaceutical purposes. Such  
20 systems include oil-in-water emulsions, water-in-oil emulsions and more complex systems known as multiple emulsions. Microemulsions that comprise thermodynamically stable systems which are normally transparent are also well known to those skilled in the art. Oil-in-water emulsions, where the continuous phase is aqueous and the disperse phase  
25 is oily in nature, can be used for a variety of purposes and administered via a variety of routes to include injection as well as administration to the eye, nose, lung, gastrointestinal tract or vagina.

Parenteral emulsions have an important role in drug delivery, diagnosis  
30 and in nutrition. The subject has been well reviewed in the literature, see

for example Davis *et al* In "Encyclopedia of Emulsion Technology",  
Becher P. Ed., Dekker, New York, Vol. 2 pp 159-238, Benita S. and  
Levy M.Y., *J. Pharm. Sci.* 82 1069 (1993) Davis S.S. *et al*, *Ann N.Y.*  
*Acad. Sci.* 507 75 (1987), and Singh M. and Ravin, L.J., *J. Parent. Sci.*  
5 *Tech.* 40 34 (1986). Emulsions given intravenously for the purposes of  
drug delivery have been well described in various patents for example,  
US 4168308, US4647586, US4816247, EP 0331755 and EP 0321429.  
The oil phase is used to carry the drug substance of interest, either with  
the drug dissolved in the oil or with the drug carried in the interfacial  
10 layer surrounding the oil droplets or a combination of both effects. The  
oil phases of choice are usually based upon pharmaceutically acceptable  
vegetable oils such as soya bean oil, olive oil, sesame oil, safflower oil,  
or more recently fractionated oils known as "medium chain triglycerides".  
The chosen emulsifier is one that is non-toxic and acceptable to regulatory  
15 authorities. Egg phospholipid (egg lecithin) has been a material of choice.  
The block copolymers known as the poloxamers (Pluronic trade name)  
have also been employed in experimental formulations. Products that have  
reached the market place include emulsions containing the anaesthetic  
agent di-isopropylphenol (propofol) and the sedative diazepam. Other  
20 emulsifying agents include bile salt derivatives as described in  
EP 0391369.

An emulsion delivery system for lipid soluble drugs has many advantages  
over other approaches such as those based upon high concentrations of  
25 surface active agent where the drug is essentially solubilised into a  
micellar phase or system based upon cyclodextrins. The latter, especially  
hydroxypropylbeta cyclodextrin, can provide an enhanced solubilisation of  
drugs. However, such cyclodextrins are known to be associated with  
toxicity problems particularly with regard to their effect on the kidney.  
30 Emulsion systems often have advantages over liposomes (phospholipid

vesicles) in that they have a higher carrier capacity for lipid soluble materials.

One problem with emulsion systems can be the poor loading of the drug  
5 into the oil phase or onto the surface of oil droplets. Such a loading is dependent upon the properties of the oil and the properties of the drug. It has been found that highly lipid soluble drugs (those with an octanol/water partition coefficient greater than 1 million) are normally well dissolved in the oil phase and satisfactory emulsions can often be  
10 prepared. However, many drugs of pharmaceutical interest do not have such a high lipid solubility or have very high melting points that result in poor solubility in the small number of pharmaceutically acceptable non-aqueous solvents. Drugs with poor lipid solubility can be given an enhanced lipid nature through the formation of prodrugs. Usually an ester  
15 linkage or a carbamate linkage is preferred because such linkages can be easily cleaved in the body to release the parent drug from the prodrug moiety. This approach has been adopted with success with the anticancer drug mitomycin. Lutz *et al.* *J. Pharm. Pharmacol.* 45, Suppl. p 59, 1992. However, such approaches result in the chemical modification of the drug  
20 and necessitate additional and expensive toxicological evaluation.

In many situations, it is desirable to have drug loadings in emulsion systems of at least 1 mg/ml or even higher. (All solubilities quoted herein are at room temperature (25°C) unless otherwise stated.) This allows a  
25 sufficient quantity of drug to be given in a minimum quantity of emulsion system. The dispersed phase of the emulsion can be increased from 5-10% to 20-30% and even to 40-50% volume in order to provide high loading where the drug is dissolved in the oil phase. Unfortunately, the greater quantity of oil employed causes the emulsion to be viscous and  
30 also leads to the administration of substantial quantities of the oil phase

(eg. triglycerides) which may have metabolic consequences. Such emulsions are also hard to homogenize and the resultant particle size can be large. Thus, it is desirable in many situations to have a high drug loading in an emulsion system with a minimum volume of injected material (both oil and water phases).

It is known in the art that the solubility of many drugs in vegetable oils can be low, even though such compounds can display high octanol-water partition coefficient. In such cases the solubility of the drug in oil can sometimes be increased by the use of oil mixtures. For example it has been shown in previous examples in the patent literature that acetylated monoglycerides as well as acetylated diglycerides can be used to improve the solubility of drugs in the oil phase of an oil-in-water emulsion, (US 4168308, Hogskilde *et al*, *Anaesthesia* 42 1045, (1987)). Moreover, the marketed emulsion products of diazepam contain both soya bean oil and acetylated monoglyceride as the disperse phase.

Liposomal Itraconazole systems have been reported in WO 93/15719. The auxiliary formulating agents demethylisosorbide and tetraglycol are used.

The difficulties of producing parenteral formulations of taxol are well described in the prior art. For example, Tarr *et al*. *Pharm. Res.* 4, 162 (1987) described an oil in water emulsion system containing 50% triacetin as an alternative system to alcohol: surfactant mixtures where the solubility of the drug in the vehicle did not exceed 0.6 mg/ml. Unfortunately their emulsion, while having a good loading of the drug, had poor pharmaceutical characteristics. The presently available commercial taxol formulations often contain large quantities of surfactant such as ethoxylated castor oil materials. These are known to be associated with undesirable side effects such as anaphylaxis. The product needs to

be diluted before use.

WO 93/136391 (EP 539215A1) and JP06092856-A refer to the use of Vitamin E as an absorption enhancing agent for the better percutaneous  
5 absorption of drugs. Vitamin E is stated to enhance the penetration of therapeutically active agents and can also act as a carrier. No mention is made of the possible use of Vitamin E (or derivatives thereof) in emulsions. Liposomal Vitamin E systems are also known (Surtres *et al*  
10 *J. Pharm. Pharmac.* 45 514, (1993), Halks-Miller *et al.*, *Lipids* 20 195 (1985), Urano *et al. Archiv. Biochem. Biophys.* 303 10 (1993).

Kato *et al* have described the blood clearance and tissue distribution of various formulations of alpha tocopherol injection after intravenous  
15 administration. Liposomal and emulsion systems are mentioned but no consideration is given to drug delivery of compounds such as antifungal agents and anticancer agents (Kato, Y. *et al. Chem. Pharm. Bull.* 41 599, 1993).

Vitamin E emulsions for use in drug therapy, for example as a vitamin  
20 preparation and as a therapeutic agent in cancer treatment, have been described previously (WO 94/21232, EP 599543). In such emulsions, the Vitamin E has been the active material and has not been used as an excipient to solubilise a poorly soluble drug.

25 US 5364631 describes the preparation of tocopherol ester liposome preparations at acid pH containing a bioactive agent. The composition is used for bioactive agents requiring or tolerating low pH conditions. Tocopherol hemisuccinate is a favoured material for liposome formation.

30 We have now surprisingly found that drugs which exhibit a low solubility

in oils, especially vegetable oil, can demonstrate high solubilities in Vitamin E, and that Vitamin E can be used to enhance the drug solubility of poorly oil soluble drugs in a lipid vehicle drug delivery composition.

- 5 The present invention therefore provides a drug delivery composition comprising a lipid vehicle containing a drug and Vitamin E to enhance the solubility of the active drug in the lipid vehicle.

The term "Vitamin E" as used herein is used to include all tocol and  
10 tocotrienol derivatives that exhibit Vitamin E activity.

The nomenclature for Vitamin E and related compounds is unclear in current practice and can vary when used by different compendia and organisations. This problem has been well addressed by Sheppard *et al.*  
15 in Vitamin E in Health and Disease, Editors Packer, L. and Fuchs, J. Dekker, New York 1993 p.9.

The United States Pharmacopoeia described Vitamin E as a form of  $\alpha$ -tocopherol. This includes d- or d, 1,  $\alpha$  tocopherol, d- or d, 1- $\alpha$ -tocopherol  
20 acetate and d- or d, 1- $\alpha$ -tocopherol succinate. The Association of Official Analytical Chemists (AOAC) states that the term Vitamin E should be used as a generic description for all tocol and tocotrienol derivatives that exhibit Vitamin E activity. Thus the term tocopherols is synonymous with Vitamin E but also for methyl tocols.  $\alpha$ -tocopherols is a trivial name  
25 without defined stereochemistry.

Tocopherol is an approved material for parenteral administration and is present in lipid emulsion systems comprising multivitamins. Vitamin E is also present in fat emulsion products for drug delivery but solely as an  
30 antioxidant at low concentrations, and certainly less than 1% of the total



emulsion. A typical example can be found in the paper by Mbela *et al.* *Int. J. Pharm.* 110 189 (1994) where tocopherol is added to an emulsion formulation as an antioxidant at a concentration of 0.02%. Tocopherol is a particularly interesting material in that it can be given in high doses orally, up to 3500 mg on a daily basis for many days. The tolerance and safety of Vitamin E has been described by Kappus and Diplock, *Free Radical Biology and Medicine* 13 55 (1992), Tomassi and Silana, *Fd. Chem. Toxic.* 24 1051 (1886). Bendich and Machlin have reviewed the clinical studies from 1986 to 1991 on the safety of Vitamin E in the monograph entitled *Vitamin E in Health and Disease*, Edited by Packer and Fuchs, Dekker, New York, 1993, p 411. For orally administered Vitamin E it is expected that 50-70% of this dose will be taken into the systemic circulation following transport through the lymphatic system. The oral uptake of Vitamin E and the effect of formulation factors is reviewed by Charman in *Lymphatic Transport of Drugs*, Editors, Charman and Stella, Chapter 4, CRC Press, 1992.

The Vitamin E is preferably in the form of the free alcohol, but suitable tocopherol derivatives are esters of tocopherol such as the linoleate, nicotinate, acetate or acid succinate ester.

We use the term drug to include all compounds which it may be desired to administer to a mammal and which are pharmaceutically, pharmacologically, therapeutically, diagnostically, cosmetically or prophylactically active or which are a prodrug for such a compound. Preferably, the drug is not a vitamin or dietary mineral such as zinc or iron.

The drug should have reasonable solubility in Vitamin E. Preferably, the drug has a solubility of at least 1mg/ml and more preferably at least

5mg/ml in Vitamin E.

The ability of a drug to dissolve in sufficient quantities in Vitamin E for use in the invention will depend on the affinity of the drug for this oil.

- 5 We have discovered that those drugs that are poorly soluble in chlorinated organic solvents such as chloroform are also poorly soluble in Vitamin E. In contrast drugs that have good solubility in chloroform have acceptable solubility in Vitamin E. Suitable drugs preferably have a solubility in chloroform of 6mg/ml or more, preferably, 10mg/ml or more.

10

- In contrast if the molecule demonstrates good solubility in methanol (more than 10mg/ml) it will demonstrate low solubility in Vitamin E (less than 1mg/ml). Thus a person skilled in the art will be able to decide whether a drug is a suitable candidate for the invention by reviewing published data on solubility in chloroform or methanol. We have defined a new parameter, the SVE ("solubility in Vitamin E") ratio, to help in this regard. This is defined as the solubility (mg/ml) in chloroform divided by the solubility (mg/ml) in methanol.

15

- 20 Those drugs with SVE greater than 10 are preferred and those materials with SVE greater than 100 are especially preferred. Some representative values are given in Table 1.

- To measure the SVE of a drug, saturated solutions of the drug are prepared in methanol and chloroform. An appropriate means of preparing a saturated solution is to suspend approximately 60mg of drug in 3ml of the solvent and stir for 24 hours at room temperature. If all of the drug dissolves during this time, further 10 mg aliquots should be added until a suspension is again formed. After 24 hours, the suspension are centrifuged or filtered to separate drug in solution from undissolved

25

30

particulate drug. The drug solutions are assayed for drug content by an appropriate means, eg. high performance liquid chromatography, and the saturated solubility calculated. The SVE is calculated by dividing the solubility in chloroform by the solubility in methanol and expressed as weight in volume (w/v):

By way of example, the SVE of itraconazole was measured as follows.

Into each of two 10ml bottles was weighed 60mg of itraconazole. To one bottle was added 3ml of chloroform. The itraconazole instantly dissolved. Further itraconazole was added in 100mg aliquots until a suspension was formed. A total of 1360mg of itraconazole was added. To the other bottle was added 3ml of methanol. A magnetic stirrer bar was added to each bottle and the contents were left to stir on a magnetic stirrer. After being left overnight to stir (18 hours), the contents of each bottle were filtered through a 0.1 $\mu$ m PTFE filter (Whatman). To assay the chloroform filtrate for itraconazole content, 0.2ml was diluted to 1000ml with a mixture of 95% of 0.01M tetrabutyl ammonium hydrogen sulphate solution in water / 5% acetonitrile. To assay the methanol filtrate for itraconazole content, 1ml was diluted to 5ml with the same diluent used for the chloroform analysis. Both samples were assayed for itraconazole content using reverse-phase high performance liquid chromatography. The concentrations of itraconazole in the diluted chloroform and methanol filtrates were 70 $\mu$ g/ml and 140 $\mu$ g/ml respectively. Thus, the solubilities of itraconazole in chloroform and methanol were 350mg/ml and 0.7mg/ml respectively. Therefore, the SVE value for itraconazole was  $350/0.7 = 500$ .

The suitability of a drug may also be determined by measuring its solubility parameter.

The ability of solvents to mix well together or for solvents to dissolve in solvents can be estimated using the procedure of solubility parameters. This method, based upon concepts of cohesion density, was developed originally by Hildebrand and refined by others for a wide range of materials. The concepts of solubility parameters is well reviewed by Barton in *CRC Handbook of Solubility Parameters and Other Cohesion Parameters*, 2nd Ed. CRC Press, 1991. Those skilled in the art often use this concept to estimate whether a particular drug (solute) will dissolve in a given solvent and the extent of such solubility. In order to do this the solubility parameter of the solute and solvent are required. While solubility parameter values are available for many solvents used in pharmaceutical formulations, solubility parameter values for drugs are not normally available. However, methods have been established wherein solubility parameter values can be calculated. The procedure described by Fedors is well known in this regard (*Polym. Eng. Sci.* 14 147, 1974).

It has been established previously that polar drug materials have solubility parameters greater than 13 and non-polar materials below 8. The solubility parameter for Vitamin E is estimated to be 9.7, similar to the value for chloroform (9.2). Methanol has a solubility parameter of 14.7. These drugs that have solubility parameter values close to that of Vitamin E would be expected to show acceptable solubility in Vitamin E. Values for the drugs listed in Table 1 are calculated according to the method of Fedors (*vide infra*).

Table 1: Solubility of drugs in organic solvents and Vitamin E

Drug	Water	Methanol	Solubility (mg/ml)		SVE *	Solubility ** Parameter
			Chloroform	Vitamin E		
Itraconazole	insol	insol	500	60	> 1000	10.6
Taxol	insol	0.03	6	11	200	11.9
Cyclosporin	Sl. sol.	0.71	363	100	520	10.7
Ergosterol	insol.	1.5	32	50	25	9.6
Cholesterol	insol.	5	200	150	40	9.6
Prednisolone	0.22	33	5.0	insol.	0.02	13.6
Amphotericin	insol.	sol.	insol.	insol.	< 1	14.4

\* SVE- ratio of solubility in chloroform to that in methanol.

\*\* - as calculated by method of Fedors (1974) *Polymer Engineer. Sci.* 14, 147, incorporated herein by reference.

Sl. sol - slightly soluble.

For the present invention we prefer drugs that have a solubility parameter value between 8 and 13 and more especially between 9 and 12. The same concepts can be applied if derivatives of Vitamin E are used. For example corresponding solubility parameters are

5

Vitamin E acetate 9.1

Vitamin E quinone 8.6

10 Drugs that are especially suitable for the emulsion formulation are antifungal agents such as itraconazole, anticancer agents such as taxol, hexamethylmelamine, penclomedine and lipophilic porphyrin derivatives, steroids such as pregnanolone, anaesthetic agents such as propofol (diisopropyl phenol), retinoid compounds, cardiovascular agents such as S-emapomil, agents such as prostaglandins, lipophilic peptides such as  
15 cyclosporin, and protein kinase C inhibitors such as dihydrosphingosine.

It is preferred if the drug loading is at least 0.1 mg/ml, more preferably 1 mg/ml and still more preferably 10 mg/ml.

20 The composition may be in the form of a liposome or more preferably an emulsion, advantageously an oil-in-water emulsion. The Vitamin E should be present in the liposome emulsion in a concentration of at least 1% in the disperse phase, preferably at least 5% and more preferably at least 10%.

25

The Vitamin E may be provided as a mixture with a pharmaceutically acceptable oil. This includes oils that can be used in an emulsion formulation which will be administered parenterally, orally, nasally, vaginally and rectally, as well as into the eye or lungs. Such oils include  
30 vegetable oils such as soybean oil, sesame oil, safflower oil, castor oil,

corn oil and olive oil, as well as marine oils such as cod liver oil and sardine oil. Oils such as squalene and squalane could also be used. In all cases the choice of the oil will be dictated by the route of administration and the metabolic character of the oil. Such mixtures of Vitamin E and vegetable oil can be readily emulsified with phospholipid emulsifiers. Vitamin E alone is difficult to emulsify with a phospholipid emulsifier on its own. Suitable phospholipid emulsifiers are egg phospholipids. Any other known emulsifying agent may also be used, such as a non-ionic surfactant.

10

In the simplest form, an oil-in-water emulsion contains three components: an oil phase, an aqueous phase and a stabiliser. The emulsion is prepared by dissolving the stabiliser in the aqueous phase. The aqueous phase is then mixed with the oil phase to form a dispersion of oil droplets. The size and size distribution of the oil droplets will depend on the method of mixing. In stable emulsions, the droplet size generally lies in the range 0.1-10 $\mu$ m. High shear mixing using equipment such as an homogeniser or a microfluidiser is the preferred method of preparing pharmaceutical emulsions. For good emulsion stability, the oil phase should comprise between 10 and 60% of the total emulsion volume. In theory, the oil phase can comprise a maximum of 74% of the total emulsion volume of an oil-in-water emulsion.

The emulsions may be administered orally, or parenterally. We use the term parenterally to include administration to the muscles, subcutaneous tissue, peritoneal cavity, venous system, arterial system, lymphatic system, spinal fluid (intrathecal, epidural) and joint cavities. Parenteral formulations will be sterile and usually pyrogen-free.

30 The emulsion can also be administered to the gastrointestinal tract or other

mucosal surfaces such as the eye, nose, vagina or rectal cavity. When formulating an emulsion for a particular route, the person skilled in the art will appreciate that the choice of emulsifier that will be employed to form a pharmaceutically stable system will be dictated by considerations of toxicity and regulatory acceptance. Thus for a parenteral emulsion and an emulsion administered to delicate surfaces such as eye, vagina or nose, the emulsifier could be a phospholipid or non-ionic surfactant in the form of a block co-polymer (Poloxamer 188). For administration to the gastrointestinal tract a wider choice of emulsifier is available to include non-ionic surfactants of different types as well as ionic emulsifiers and natural gums.

Examples include sodium oleate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, gum acacia, gelatin, methylcellulose and gum tragacanth.

When the emulsion intended for injection contains a high content of Vitamin E in the oil phase (that is greater than 50%) the preferred emulsifier is a block copolymer such as poloxamer 188.

20

The emulsion of the invention is useful for oral administration. Itraconazole and similar drugs are known to have a poor and variable bioavailability from the gastrointestinal tract largely, because of the poor solubility of the drug in the fluids of the stomach and intestine. By preparing a self-emulsifying or well solubilised oily formulation of the drug where Vitamin E is used as a drug solubilizing agent, the oral absorption of itraconazole has been improved. This approach greatly minimises the volume of oil vehicle required as compared to a conventional emulsion prepared from vegetable oils or even fish (marine) oils. Thus, by dissolving itraconazole in Vitamin E, it has been found

30



possible to produce a more reliable and convenient oral formulation. A spontaneously emulsifying system can be prepared using various methodologies prescribed in the prior art.

- 5 By mixing the solution of drug in Vitamin E with a pharmaceutically acceptable oil-in-water emulsifier, a formulation can be prepared which readily disperse in contact with aqueous media. Such emulsifiers should be miscible with Vitamin E and include, but are not limited to, polyoxyethylene sorbitan fatty acid esters (eg. Tween®), polyoxyethylene  
10 alkyl ethers (eg. Brij®) and polyglycolized glycerides (eg. Labrasol®, Gattefosse). Such formulations are suitable for filling into pharmaceutical capsules made of materials such as gelatin or starch.

- Surfactant systems that have been approved by regulatory authorities are  
15 well known. In the gastrointestinal tract the system can emulsify spontaneously because of the low interfacial tension created by the addition of the emulsifier and co-surfactant systems.

- Thus, by using Vitamin E, either alone or mixed with a pharmaceutically  
20 acceptable oil, we have found that the solubility of certain poorly soluble drugs in a lipid system can be greatly increased.

- In particular in studies on the preparation of emulsions of the antifungal drug itraconazole and the anticancer agent taxol, we have found that the  
25 substances have a surprisingly high solubility in Vitamin E. These drugs themselves are poorly soluble in conventional vegetable oils such as soya bean oil. For example for itraconazole and taxol the solubility of the drug in vegetable oils is 400 microgram/ml or less. Similar values are found with other vegetable oils such as sesame oil and fractionated medium chain  
30 triglycerides. However, the drugs display solubility in Vitamin E

(tocopherol). This represents a most surprising increase in solubility compared to a simple triglyceride vegetable oil. We have also found that it is possible to mix vegetable oil with Vitamin E and thereby provide various levels of enhanced solubility of drugs so that they may be administered parenterally as an emulsion formulation.

Emulsions containing various quantities of soy bean oil mixed with tocopherol and added itraconazole have been prepared. In this way we have been able to prepare emulsions containing 2 mg/ml of the antifungal agent Itraconazole. This is much higher than has been hitherto reported for non Vitamin E formulations. We have also been able to prepare liposomal systems with a high drug loading by dissolving Itraconazole in Vitamin E and then making a liposomal product using conventional procedures. Similarly emulsion products containing a loading of the anticancer drug taxol at a quantity of at least 1 mg/ml have been prepared. Once again this is a higher concentration of drug in a vegetable oil based emulsion that has been reported hitherto.

The liposome formulation can be prepared according to well established methods known to those skilled in the art (for example see Chapter 1, Preparation of liposomes, in *Liposome drug delivery systems*, Betageri *et al.*, Technomic Publishing Co. 1993).

Liposomes of different structures, namely multilamellar vesicles, small unilamellar vesicles and large unilamellar vesicles, can be produced. The basic constituent is a phospholipid derived from both natural and synthetic sources. The main material is phosphatidylcholine but other neutral and charged lipids can be included. Cholesterol can also be added.

The traditional way to produce liposomes is to dissolve the constituent

- lipids in an organic solvent such as chloroform. A lipid soluble drug can be co-dissolved at this stage. The mixture can be filtered to remove insoluble matter and the solvent then removed under conditions of temperature and pressure that result in the formation of a dry lipid film.
- 5 This film is then hydrated using an aqueous medium that can contain hydrophilic compounds to include a drug substance. This hydration process can be controlled so as to control the nature of the resultant liposome formed. When hydration occurs under hand shaking multilamellar liposomes normally result. Smaller liposomes can be
- 10 produced by the use of sonication and high pressure homogenisation. A French pressure cell can also be used as described by Hamilton and Guo in *Liposome Technology*, Vol. 1. Gregoriadis, Editor, CRC Press, 1984, p. 37.
- 15 Other methods that employ the injection of water immiscible solvents such as ether containing the lipids into an aqueous phase have been described. Other methods include the detergent dialysis method, reverse phase evaporation and extrusion processes. The selection of the method of preparation to provide good drug retention, trapping efficiency has been
- 20 well described in the prior art (see Betageri *et al*) thereby allowing the person skilled in the art to prepare a liposome system appropriate to the needs of a particular drug. The present invention is especially useful for drugs that have poor water solubility and would therefore be incorporated into the liquid layer of the liposomal system. The addition of Vitamin E
- 25 leads to an enhanced level of incorporation.

Preferred features of the invention will now be described in more detail in the following Examples and Figures wherein.

- 30 Figure 1 shows the effect of emulsifier concentration on the emulsion

particle size. The oil phase was a mixture of Vitamin E and soybean oil in weight ratio 1:1. A. Pluronic P105 B. Pluronic F127.

Figure 2 shows the effect of the amount of Vitamin E in oil phase on the particle size of the emulsion. The other component of the oil phase was soybean oil. The concentration of the emulsifier was 4% (w/v) and it was Pluronic P105 (A) or Pluronic F127 (B).

Figure 3 shows the particle size as a function of the weight ratio of the surfactant (Pluronic P105 or Pluronic F127) and phosphatidylcholine in their mixture used as the emulsifier. The oil phase was 10% v/v and it was composed of Vitamin E and soybean oil in weight ratio 1:1.

Emulsions of candidate drugs in emulsion formulations were prepared using standard processes such as homogenisation using a microfluidizer (Microfluidic Corporation) or an ultrasonic probe (Dawe, Branson Soniprobe system). The emulsions were prepared by dissolving the drug in the mixture of oil and Vitamin E (or Vitamin E alone), adding the aqueous phase and then preparing a pre-emulsion by use of a high speed stirrer followed by homogenisation using the microfluidizer or ultrasonic method. The aqueous phase of the emulsion contained the dissolved (non-ionic surfactant) or dispersed (phospholipid emulsifier). Emulsions were characterised by means of laser diffractometer (Malvern Mastersizer) and photon correlation spectroscopy (Malvern 4900). Terminal sterilization was achieved using a rotating bench autoclave that could handle 5ml samples under nitrogen (120°C 15 psi (103 KPa) for 10 mins).

**Example 1***Emulsion 1*

	Soybean oil	15%
5	Myvacet oil (acetylated monoglycerides)	15%
	Phospholipid emulsifier (Epikuron 200 SH)	4%
	Vitamin E	5%
	Water to	100% (81 ml)
	Itraconazole loading	1.5 mg/ml

10

The oils (myvacet and soybean oil) and Vitamin E together with itraconazole were mixed and heated to 60°C until the solution became clear. Separately the aqueous phase containing the phospholipid emulsifier was heated to 60°C and blended by stirring at 700 RPM for 2 minutes.

15 The oil phase was then added to the aqueous mix at a rate of 30 ml/min and the resultant mix blended at 13,500 RPM for a further 10 minutes. This formed the pre-emulsion which was then passed through a microfluidizer at 1500 psi for 6 cycles through the machine. The exit temperature was 30-40°C.

20

**Example 2***Emulsion 2*

	Soybean oil	30%
25	Phospholipid emulsifier (Epikuron 200 SH)	4%
	Vitamin E	5%
	Water to	100% (7 ml)
	Itraconazole loading	1.4 mg/ml

30 The emulsion was prepared as in Example 1 and the mixture sonicated (30

sec on/off cycle) for 5 mins. on a Microson system at a power of 50%.

### Example 3

#### *Emulsion 3*

5

	Soybean oil	15%
	Myvacet oil	15%
	Epikuron 200 SH	4%
	DMPG (dimyristoyl phosphatidyl glycerol)	0.05%
10	Vitamin E	5%
	Water to	100% (60 ml)
	Itraconazole loading	1.5 mg/ml

The emulsion was prepared as in Emulsion 1. A stable emulsion resulted.

15

### Example 4

#### *Emulsion 4*

	Soybean oil	1 ml
20	Vitamin E	0.25 ml
	Egg yolk phospholipid	200 mg
	Water to	3 ml
	Itraconazole loading	1.7 mg/ml

25 The emulsion was prepared as in Emulsion 1. A stable emulsion resulted.

### Example 5

#### *Liposome 1*

30	Phospholipid (Epikuron 200 SH)	740 mg
----	--------------------------------	--------

Vitamin E	198 mg
Water	5 ml
Itraconazole loading	2 mg/ml

- 5 Phospholipid, Epikuron 200 SH, Vitamin E and itraconazole were dissolved in a mixture of chloroform : methanol (2 : 1). The solvent was removed by thin film evaporation. This was then rotary evaporated until the solvent was removed and the lipid film hydrated with water (5 ml). This solution was then heated to 60°C and allowed to cool. The  
10 itraconazole content was 2.0 mg/ml.

- A further series of experiments has been conducted to investigate different emulsion formulations where the amount of Vitamin E, the type of oil and emulsifier (phospholipid or non-ionic surfactant) have been varied. It is  
15 clear from these experiments that a person skilled in the art could undertake similar studies in order to select the optimum system for a particular application.

- When mixed with soybean oil, (Vitamin E is freely soluble in vegetable  
20 oil) emulsions were obtained using egg yolk phospholipid (4%) as emulsifier when the ratio of Vitamin E to vegetable oil was less than 1 : 2.

- Emulsification of undiluted Vitamin E was achieved using a non-ionic  
25 surfactant (Poloxamer 188) as emulsifier. Furthermore various mixtures of Vitamin E and vegetable oils were all well emulsified by Poloxamer 118. Some relevant examples are given below by way of illustration.

#### Example 6

- 30 *Emulsion 5*

To investigate whether a non-ionic emulsifier can be used instead of a phospholipid emulsifier to prepare Vitamin E for use in the invention.

	Poloxamer 188	2%
5	Soybean oil	20%
	Vitamin E	10%
	Water to	10 g

The emulsion was prepared by sonication as for Emulsion 2. A stable  
10 emulsion was prepared, mean size 227 nm.

#### Example 7

##### *Emulsion 6*

15 To investigate whether Vitamin E emulsions could be prepared without the addition of vegetable oil using phospholipid as the emulsifier.

	Vitamin E	10% or 50%
	Egg yolk phospholipid	from 0.4 - 4%
20	Water	to 10 g

Stable emulsions were not formed.

#### Example 8

##### 25 *Emulsion 7*

To investigate whether Vitamin E can be emulsified by Poloxamer 188 without the addition of vegetable oil using the sonification procedure as employed for Emulsion 2.



Vitamin E	5%
Poloxamer 188	0.2%
Water	to 10 g

- 5 An emulsion was formed that had a mean size of 630 nm.

### Example 9

#### *Self-emulsifying oral formulation 1*

- 10 500 mg of itraconazole was added to 3600 mg of Vitamin E. The mixture was warmed to 60°C and stirred until the itraconazole had dissolved. The solution of itraconazole in Vitamin E was cooled to room temperature and 900 mg of polysorbate (Tween) 80 added. Injection moulded starch capsules (Capill, Capsugel) were each filled with 500 mg of the mixture.
- 15 Thus each capsule contained 50 mg itraconazole, 360 mg of Vitamin E and 90 mg of polysorbate 80.

### Example 10

#### *Preparation of emulsions with different oil content*

20

- To investigate the effect of total oil content (1:1 ratio of Vitamin E to soybean oil) on emulsion formation and particle size. Emulsions were prepared using the ultrasonic method (output 30%, 5 minutes sonication time). The emulsifier was a poloxamer 407 (Pluronic 127) at 2% w/v
- 25 concentration. Table 2 shows the effect on particle size and size polydispersity of increasing the oil content in the emulsion when the oil phase is composed of equal weight ratios of soya oil and Vitamin E. Emulsions could be prepared with up to 30% v/v of oil.

**Table 2**

*Particle size of emulsions with different oil content. The oil phase was composed of soya oil and Vitamin E in weight ratio 1:1 and the emulsifier was Pluronic-127 at 2% (w/v).*

5

10

Sample	Size nm	Polydispersity
5% oil	168.5 $\pm$ 6.6	0.299 $\pm$ 0.058
10% oil	201.5 $\pm$ 3.6	0.136 $\pm$ 0.076
15% oil	251.6 $\pm$ 2.4	0.148 $\pm$ 0.040
20% oil	306.0 $\pm$ 27.6	0.348 $\pm$ 0.126
30% oil	462.2 $\pm$ 54.1	0.480 $\pm$ 0.069

**Example 11**15 *Preparation of emulsions using Spans and Tweens*

To investigate the effect of different emulsifiers. Satisfactory emulsions could be prepared using Polysorbate 20, 40, 60 (Tween 20, Tween 40 and Tween 60) as emulsifiers. Emulsions were prepared by the sonication method as in example 10, at either 10 or 20% v/v oil phase comprising a 1:1 ratio Vitamin E:Soybean oil (w/w). The emulsifier concentration was 4% w/v in all cases. No satisfactory emulsions could be prepared with Polysorbate 65 (Tween 65) and Sorbitan laurate (Span 20). Thus, it may be concluded that the HLB (hydrophilic-lipophilic balance) of the emulsifier should, at least in this system, be greater than 11 (Table 3).

25

**Table 3**

*Particle size of emulsions prepared using different emulsifiers. The oil phase was soya oil, Vitamin E 1:1 (w/w) and the emulsifier concentration was 4% (w/v)*

5

10

15

Sample	Size nm	Polydispersity	HLB
Tween 20 10% oil	151.6 $\pm$ 1.4	0.243 $\pm$ 0.022	16.7
Tween 20 10% oil	166.8 $\pm$ 1.8	0.218 $\pm$ 0.021	
Tween 20 20% oil	247.4 $\pm$ 4.1	0.290 $\pm$ 0.039	
Tween 40 10% oil	212.6 $\pm$ 4.0	0.264 $\pm$ 0.034	15.6
Tween 40 20% oil	285.8 $\pm$ 4.2	0.307 $\pm$ 0.041	
Tween 80 10% oil	194.4 $\pm$ 2.9	0.360 $\pm$ 0.028	15
Tween 80 20% oil	341.0 $\pm$ 10.4	0.377 $\pm$ 0.082	
Tween 65 10% oil	no emuls.		10.5
Tween 65 20% oil	> >		
Span 20 10% oil	no emuls.		8.6
Span 20 20% oil	> >		

**Example 12**20 *Preparation of emulsions using poloxamers and poloxamines*

To investigate the effect of different block copolymers as emulsifiers. Emulsions were prepared by the sonication method as in example 10, using 10 or 20% v/v oil phase comprising a 1:1 ratio (w/w) of Vitamin E to Soybean oil. The block copolymers were used as emulsifiers at a concentration of 4% v/v. Satisfactory emulsions could be prepared using surfactants of the poloxamer and poloxamine series (block copolymers of polyoxyethylene and polyoxypropylene, commercially available from Wyandotte Chemical as Pluronics and Tetronics). Particle size and polydispersity data are given in Table 4.

30

**Table 4**

*Particle size of emulsions prepared using different poloxamers (Pluronic) and poloxamines (Tetronic). The oil phase was composed of soya oil and Vitamin E in weight ratio 1:1 and the concentration of the various emulsifiers was 4% (w/v).*

Sample	Size nm	Polydispersity
Pluronic L35 10% oil	147.8 $\pm$ 1.8	0.118 $\pm$ 0.031
Pluronic F127 10% oil	188.4 $\pm$ 2.7	0.154 $\pm$ 0.041
Pluronic F127 20% oil	230.8 $\pm$ 4.2	0.116 $\pm$ 0.077
Pluronic L44 10% oil	154.8 $\pm$ 2.6	0.146 $\pm$ 0.046
Pluronic P105 10% oil	132.7 $\pm$ 1.1	0.158 $\pm$ 0.036
Pluronic P105 20% oil	212.0 $\pm$ 4.7	0.239 $\pm$ 0.062
Tetronic 704 10% oil	155.8 $\pm$ 3.8	0.252 $\pm$ 0.021
Tetronic 904 10% oil	154.2 $\pm$ 5.2	0.206 $\pm$ 0.041
Tetronic 904 20% oil	258.7 $\pm$ 3.5	0.244 $\pm$ 0.038
Tetronic 1104 10% oil	193.2 $\pm$ 5.5	0.254 $\pm$ 0.044
Tetronic 1104 20% oil	321.6 $\pm$ 3.7	0.436 $\pm$ 0.018
Tetronic 1504 10% oil	137.6 $\pm$ 1.5	0.185 $\pm$ 0.032
Tetronic 1504 20% oil	261.4 $\pm$ 5.4	0.282 $\pm$ 0.054

**Example 13***The effect of surfactant concentration*

25

To investigate the effect of emulsifier concentration. Emulsions were prepared by sonication as in example 10, using a 10 or 20% v/v oil phase content comprising a 1:1 w/w ratio of Vitamin E to Soybean oil. The emulsifiers were Pluronic 105 and Pluronic 127. The emulsions were prepared at increasing concentration of these two emulsifiers from 0 to

30

10% w/v. It can be seen from Figure 1 that above 2.5% emulsifier content, no special advantage is gained by the addition of more emulsifier.

#### Example 14

##### 5 *The effect of Vitamin E in the oil phase*

To investigate the effect of combining a block copolymer and phospholipid emulsifier. Vitamin E is not an easy material to emulsify and therefore a preferred embodiment of the invention is to mix the Vitamin E with a vegetable oil such as Soya bean oil, olive oil, sesame oil, castor oil,  
10 peanut oil, corn oil. Emulsions were prepared by the ultrasonication method described in Example 10. The Vitamin E content of the oil phase was increased from 0 to 60% w/w. For Pluronic 105, the total oil content of the emulsions was at 10, 20 and 30% v/v. Poloxamines were used as  
15 emulsifiers at 4% w/v concentration. For Pluronic 127 the total oil content was 20% v/v. The properties of the emulsion (particularly particle size) were measured. It can be seen from Figure 2 that a 50:50 (1:1) mixture of Vitamin E to Soya oil was the limit for a satisfactory emulsion when the emulsifier was Pluronic P105. When using Pluronic F127,  
20 suitable emulsions could be at higher contents of Vitamin E in the oil phase.

#### Example 15

##### 25 *The effect of a combined emulsifier of phospholipid and pluronic block copolymer*

To investigate the effect of combining a block copolymer and phospholipid emulsifier. A series of emulsions was prepared wherein the emulsifier was a mixture of hydrogenated egg phospholipid with poloxamer  
30 surfactants. The concentration of the phospholipid was held constant at

2 or 4% w/v and Pluronic 105 and F127 added in increasing amounts. The particle size results are given in Figure 3. The addition of the poloxamers had a beneficial effect on particle size when the weight ratio of poloxamer to phospholipid was greater than 0.3.

5

### Example 16

#### *Emulsions containing Taxol*

Taxol can be solubilized into Vitamin E up to a concentration of 40 mg/g dependent on temperature. Taxol was dissolved in Vitamin E in concentrations 10, 20 and 30 mg/g and emulsions with 10% v/v oil phase (Vitamin E, Soybean oil 1:1 w/w ratio) were prepared using different emulsifiers using the sonication method so that the initial concentration of the drug in the emulsion was 0.5, 1 and 1.5 mg/ml, respectively. The measurements of the incorporation efficiency were performed one day after the preparation. The results, which are summarized in Table 5, showed that the incorporation of taxol was lowered when the initial amount of the drug in the oil phase was increased. The determination of the drug concentration in the oil phase showed that with Tetronic 1504, the emulsifier with the highest molecular weight, had an advantage over Pluronic P105 since it resulted in a more efficient incorporation of taxol in the emulsion.

**Table 5**

*Physical characteristics and taxol incorporation efficiency for emulsions containing 10% v/v oil phase (Vitamin E, Soybean oil 1:1 w/w)*

5	<b>Emulsifier</b>	<b>Initial taxol concentration (mg/ml)</b>	<b>Size (nm)</b>	<b>Polydispersity</b>	<b>% taxol incorporation</b>
	Pluronic P105 (4% w/v) > >	0.5	122.6 ± 1.2	0.204 ± 0.019	100
		1.0	129.4 ± 1.9	0.174 ± 0.020	41
		1.5	126.0 ± 2.6	0.187 ± 0.048	13
10	Tetronic 1504 (4% w/v) > >	0.5	130.0 ± 1.3	0.134 ± 0.028	88
		1.0	131.3 ± 2.0	0.146 ± 0.026	61
		1.5	134.0 ± 1.1	0.142 ± 0.014	49
	PC Pluronic F127 (1.25% w/v) > >	0.5	185.3 ± 7.8	0.225 ± 0.082	46
		1.0	177.2 ± 4.6	0.243 ± 0.083	30
		1.5	179.4 ± 4.6	0.219 ± 0.043	37
15	PC Pluronic F108 (1.25% w/v) > >	0.5	177.4 ± 4.0	0.225 ± 0.044	40
		1.0	172.6 ± 3.9	0.210 ± 0.38	51
		1.5	181.2 ± 3.7	0.214 ± 0.025	35

When the oil content of the emulsion increased to 20% v/v, the incorporation of taxol was improved (Tables 6 and 7). The nature of the material used as emulsifier affected the percentage of the drug that was finally incorporated in the emulsion droplets. More hydrophilic emulsifiers, such as Pluronic F127 and Pluronic F108, gave better results.

**Table 6**

*Physical characteristics and taxol incorporation efficiency for emulsions containing 20% oil phase (vitamin E, soybean oil 0.6:1 w/w). The concentration of the emulsifier was 4% (w/w).*

5

Emulsifier	Initial taxol concentration (mg/ml)	Size (nm)	Polydispersity	% taxol incorporation
Pluronic P105	2.25	190.6 $\pm$ 1.8	0.097 $\pm$ 0.029	72
Pluronic F127	2.25	201.9 $\pm$ 2.0	0.085 $\pm$ 0.037	79
Pluronic F108	2.25	203.0 $\pm$ 1.9	0.081 $\pm$ 0.017	81
Tetronic 1504	2.25	205.0 $\pm$ 2.5	0.108 $\pm$ 0.036	62

10

**Table 7**

*Physical characteristics and taxol incorporation efficiency for emulsions containing 20% oil phase (vitamin E, soybean oil 1:1 w/w). The concentration of the emulsifier was 4% (w/v).*

15

Emulsifier	Initial taxol concentration (mg/ml)	Size (nm)	Polydispersity	% taxol incorporation
Pluronic P105	3.0	200.1 $\pm$ 2.6	0.118 $\pm$ 0.026	80
Pluronic F127	3.0	197.6 $\pm$ 3.0	0.141 $\pm$ 0.050	82
Tetronic 1307	3.0	199.0 $\pm$ 2.6	0.149 $\pm$ 0.036	56

20

### Emulsifiers

25

Trade and approved names.

Tetronic  $\equiv$  poloxamine

(polyethylene oxide, polypropylene oxide block copolymers based on ethylenediamine)

30



Pluronic  $\equiv$  poloxamer

(polyoxyethylene oxide, polypropylene oxide block copolymers)

Pluronic  $\equiv$  Poloxamer

5	P105	335
	F127	407
	F108	338
	L35	105
	L44	124

CLAIMS

1. A drug delivery composition comprising a lipid vehicle containing drug and Vitamin E to enhance the solubility of the drug in the lipid vehicle.
2. A drug delivery composition according to claim 1 wherein the lipid vehicle is a liposome or an emulsion system.
3. A drug delivery composition according to claim 1 or 2 wherein the drug has a solubility of at least 1mg/ml in Vitamin E.
4. A drug delivery composition according to claim 1 or 2 wherein the drug has a solubility in chloroform of 6mg/ml or more.
5. A drug delivery composition according to claim 4 wherein the ratio of the respective solubility of the drug in chloroform and methanol is greater than 10.
6. A drug delivery composition according to any one of the preceding claims wherein the composition is an oil-in-water emulsion system and the Vitamin E is present in a concentration of at least 1% in the disperse phase of the emulsion.
7. A drug delivery composition according to claim 6 wherein the emulsion additionally comprises a pharmaceutically acceptable oil, and wherein the Vitamin E is provided as a mixture with the pharmaceutically acceptable oil.
8. A drug delivery composition according to claim 6 or 7 wherein the

emulsion further comprises an emulsifying agent.

9. A drug delivery composition according to any one of the preceding claims wherein the drug is an anti-fungal agent, an anti-cancer agent, a  
5 retinoid or a steroid.

10. A drug delivery composition according to any one of claims 1 to 8 wherein the drug is itraconazole, pregnanolone, taxol or a derivative thereof or cyclosporin.

10

11. A method of administering a drug to a patient the method comprising administering to the patient a drug delivery composition according to any one of the preceding claims.


15 12. A method according to Claim 11 wherein the drug is administered by injection or by administration to any of the eye, the nose, the lung, the gastrointestinal tract, the rectum or the vagina.

13. Use of Vitamin E in the manufacture of a drug delivery  
20 composition as defined in any one of Claims 1 to 10.

14. A method of making a drug delivery composition according to any one of Claims 1 to 12 comprising admixing the lipid vehicle, the drug and Vitamin E.


1/5

FIGURE 1A




2/5

FIGURE 1B



3/5

FIGURE 2A



4/5

FIGURE 2B





FIGURE 3





# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 96/01758

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/107 A61K9/127 A61K47/22

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X P,Y	WO,A,95 31217 (DUMEX) 23 November 1995 see the whole document ---	1-14 1-14
Y	WO,A,89 03689 (THE LIPOSOME COMPANY) 5 May 1989 see the whole document ---	1-14
P,Y	US,A,5 478 860 (JEFFERY J. WHEELER ET AL.) 26 December 1995 see claims 1,4,5,10 see column 11; example 3 ---	10
Y	DE,A,43 22 826 (GALENIK LABOR FREIBURG) 12 January 1995 see column 2, line 64 - column 3, line 25 see column 6; example 4 --- -/-	10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 December 1996

Date of mailing of the international search report

17.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

# INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/GB 96/01758

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>EP,A,0 391 369 (YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY) 10 October 1990 cited in the application see page 4, line 6 - line 8 see page 4, line 32 - line 33 see page 5, line 3 - line 10 see page 7, line 39 - line 45; example 1 -----</p>	10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 96/01758

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9531217	23-11-95	AU-A- 2670595	05-12-95
WO-A-8903689	05-05-89	CA-A- 1333360	06-12-94
		DE-A- 3883246	16-09-93
		DE-T- 3883246	02-12-93
		EP-A- 0382779	22-08-90
		JP-T- 3500651	14-02-91
		US-A- 5364631	15-11-94
US-A-5478860	26-12-95	NONE	
DE-A-4322826	12-01-95	AU-A- 7345794	06-02-95
		AU-A- 7385094	06-02-95
		BR-A- 9407002	03-09-96
		CA-A- 2164100	19-01-95
		CN-A- 1128495	07-08-96
		CZ-A- 9600045	17-04-96
		DE-D- 4494850	22-08-96
		WO-A- 9501785	19-01-95
		WO-A- 9501786	19-01-95
		EP-A- 0710103	08-05-96
		EP-A- 0710104	08-05-96
		FI-A- 960032	09-02-96
		FI-A- 960042	04-01-96
		HU-A- 73427	29-07-96
		HU-A- 73661	30-09-96
		NO-A- 960062	05-01-96
		NO-A- 960069	05-01-96
		NZ-A- 269552	26-07-96
		NZ-A- 269808	26-07-96
		PL-A- 312255	01-04-96
EP-A-391369	10-10-90	IL-A- 93558	27-11-95
		AT-T- 110563	15-09-94
		AU-B- 614465	29-08-91
		AU-A- 5292790	11-10-90
		CA-A, C 2013755	05-10-90
		DE-D- 69011922	06-10-94
		DE-T- 69011922	12-01-95
		JP-A- 2290809	30-11-90

